首页> 美国政府科技报告 >Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers. Final Guidance

【24h】

Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers. Final Guidance

机译：公众，FDa咨询委员会成员和FDa工作人员指南：咨询委员会成员的财务利益信息和豁免的公开可用性。最终指导

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

This guidance is intended to help the public, Food and Drug Administration (FDA) advisory committee members, and FDA staff to understand and implement statutory requirements and FDA policy regarding public availability of information about financial interests and waivers granted by FDA to permit individuals to participate in advisory committee meetings subject to the Federal Advisory Committee Act (FACA) (5 U.S.C. App. 2). This guidance describes the basis and provides a format for public disclosure of certain financial interests by special Government employees (SGEs) and regular Government employees participating in these advisory committee meetings, and provides a format for FDA waivers allowing participation in these meetings. This guidance also explains how and when these documents will be made publicly available by FDA.

著录项

作者

展开▼
作者单位

展开▼
年度 2012
页码 1-15
总页数 15
原文格式 PDF
正文语种 eng
中图分类工业技术;
关键词
US FDA ; Participation ; Advisory committees ; Guidance ; Waivers ; Financial statements ; Government employees ; Regulations ; Conflict of interest ; Disclosure ; Government agencies ; Statutes ; Implementation;

机译：美国FDa;参与;咨询委员会;指导;豁免;财务报表;政府雇员;法规;利益冲突;披露;政府机构;章程;实施;

相似文献

外文文献
专利

1. FDA Guidance on Public Availability of Advisory Committee Members' Financial Interest Information and Waivers [J] . Biotechnology Law Report . 2007,第6期

机译：FDA咨询委员会成员的财务利益信息和豁免公开指南
2. Guidance for Industry and FDA Staff: Procedures for Determining Conflict of Interest and Eligibility for Participation in FDA Advisory Committees [J] . Biotechnology Law Report . 2007,第3期

机译：工业界和FDA员工指南：确定利益冲突和参与FDA咨询委员会资格的程序
3. Advisory Committee Split On Whether FDA Should Draft Nanotech Guidance [J] . Elizabeth Crawford The Rose Sheet: Toiletries, Fragrances and Skin Care . 2008,第30期

机译：咨询委员会就FDA是否应起草纳米技术指导意见分歧
4. Status of Decision-making Advisory Committee in the Innovation of Social Governance and Its Significance: Based on an Investigation of Zhuhai "Advisory Committee" [C] . Linsheng Xiao, Qi Zhu, Chih Huang, International Conference on Contemporary Education, Social Sciences and Humanities . 2018

机译：社会治理创新决策咨询委员会的现状及其意义 - 基于珠海“咨询委员会”调查
5. THE NATIONAL ADVISORY COMMITTEE ON OCEANS AND ATMOSPHERE: THE EFFECTIVENESS OF A PUBLIC ADVISORY COMMITTEE [D] . WILSON, ARTHUR SYDNEY 1983

机译：全国海洋和海洋咨询委员会：公众咨询委员会的效力
6. Code of practice and guidance on human genetic testing services supplied direct to the public. Advisory Committee on Genetic Testing. [O] . J C Barber 1998

机译：直接向公众提供的人类基因检测服务业务守则和指南。基因检测咨询委员会。
7. "Code of practice and guidance on human genetic testing services supplied direct to the public". Advisory Committee on Genetic Testing. [O] . Barber, J C 1998

机译：“直接向公众提供的人类基因检测服务业务守则和指南”。基因检测咨询委员会。
8. Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers [R] . 2008

机译：公众，FDa咨询委员会成员和FDa工作人员指南：咨询委员会成员的财务利益信息和豁免的公开可用性

Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers. Final Guidance

摘要

著录项

相似文献

相关主题

期刊订阅